RNAssist and Rapid Labs agree on a manufacturing and supply agreement for genoPHIX and vivoPHIX

RNAssist (www.RNAssist.com) has developed several universal biological sample stabilization, fixation and microbial inactivation reagents. Rapid Labs (www.rapidlabs.co.uk) a manufacturer and supplier of medical and veterinary diagnostic reagents, announced today an agreement under which RNAssist will grant Rapid Labs the right to manufacture and supply the genoPHIX™ and vivoPHIX™ products.

Image credits: Rapid Labs

Rapid Labs will manufacture, market and supply the technology worldwide for Research Use Only (RUO) applications in order to facilitate and expand the world-wide availability of RNAssist’s reagents for use across a broad range of research sectors including fundamental and applied research, drug development, food safety and biotechnology.

The technology is based, in part, on the discovery by RNAssist that certain massively hydrogen-bonded organic liquids protect RNA, DNA, proteins and phosphoproteins from damage during transport and storage, in both liquid biopsies and solid biological samples, permitting effortless integration with existing downstream multi-analyte sample preparation workflows.

The genoPHIX™ and vivoPHIX™ reagents will be supplied for a broad range of applications including sample storage and transport, RNAseq, scRNA-seq, scDNA-seq, metagenomics, multi-omics, virus and bacterial inactivation, and tissue fixation and staining (IHC, IF and ISH).

This manufacturing and supply agreement strengthens the existing relationship between RNAssist and Rapid Labs in the area of sample stabilization and fixation technologies. It demonstrates our focus on rapidly expanding the solid pre-existing base of our 240 member evaluation community including world-class researchers at leading academic institutions and, major diagnostic and pharmaceutical companies.”

Andrew Goldsborough, the CSO of RNAssist

We are thrilled to start this new partnership with RNAssist. Their extensive experience of nucleic acid chemistry and biomolecule stabilization coupled with our experience in manufacturing and international sales makes it a very promising and exciting opportunity for both parties. Our extensive network of customers, distributors, agents and NGOs across the world will offer a substantial platform for introducing RNAssist products into the global scientific market. The RNAssist range will offer significant benefits to many customers – not only from an economic perspective (RNAssist-treated samples can be shipped and stored at room temperature, eliminating the need for expensive cold-chain transport), but from a safety handling point of view too (RNAssist has the capability to inactivate many viruses and bacteria, offering the potential to work in lower biosecurity settings). What’s more, the unique properties of vivoPHIX™ enabling single-cell analysis is truly exciting and opens up a huge range of opportunities for research laboratories.” 

Ian Christopher, CEO of Rapid Labs

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Rapid Labs Ltd. (2020, January 27). RNAssist and Rapid Labs agree on a manufacturing and supply agreement for genoPHIX and vivoPHIX. News-Medical. Retrieved on May 27, 2020 from https://www.news-medical.net/news/20200123/RNAssist-and-Rapid-Labs-agree-on-a-manufacturing-and-supply-agreement-for-genoPHIX-and-vivoPHIX.aspx.

  • MLA

    Rapid Labs Ltd. "RNAssist and Rapid Labs agree on a manufacturing and supply agreement for genoPHIX and vivoPHIX". News-Medical. 27 May 2020. <https://www.news-medical.net/news/20200123/RNAssist-and-Rapid-Labs-agree-on-a-manufacturing-and-supply-agreement-for-genoPHIX-and-vivoPHIX.aspx>.

  • Chicago

    Rapid Labs Ltd. "RNAssist and Rapid Labs agree on a manufacturing and supply agreement for genoPHIX and vivoPHIX". News-Medical. https://www.news-medical.net/news/20200123/RNAssist-and-Rapid-Labs-agree-on-a-manufacturing-and-supply-agreement-for-genoPHIX-and-vivoPHIX.aspx. (accessed May 27, 2020).

  • Harvard

    Rapid Labs Ltd. 2020. RNAssist and Rapid Labs agree on a manufacturing and supply agreement for genoPHIX and vivoPHIX. News-Medical, viewed 27 May 2020, https://www.news-medical.net/news/20200123/RNAssist-and-Rapid-Labs-agree-on-a-manufacturing-and-supply-agreement-for-genoPHIX-and-vivoPHIX.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.